Glucolón

Glucolón is a prescription medication that contains the sulfonylurea glibenclamide as its active ingredient, supplied in an oral tablet form for use. It is marketed in the European Union and belongs to the second‑generation sulfonylurea class, which works by stimulating insulin release from pancreatic β‑cells. Glucolón is indicated for the management of blood glucose levels in adults with type 2 diabetes mellitus. It is prescribed as part of a treatment plan.

Glucolón is used in clinical practice to help control hyperglycemia in patients with type 2 diabetes mellitus.

- As an adjunct to diet and exercise, it lowers elevated blood glucose levels. - It may be used when metformin alone does not achieve target glycemic control. - It is appropriate for adult patients whose pancreatic β‑cell function is still present. - It can be part of a combination regimen with other oral antidiabetic agents, provided dosing is individualized. - It may be considered for patients who prefer a once‑daily oral therapy over injectable options. - It is not indicated for type 1 diabetes or for diabetic ketoacidosis.

Glucolón, like other sulfonylureas, can cause a range of adverse effects that vary in frequency and severity. These effects are reported in clinical studies and post‑marketing surveillance, and patients should be monitored regularly.

Common: - Low blood sugar (hypoglycemia), especially if meals are missed or delayed. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity. - Mild fatigue or weakness. - Increased urination or thirst, reflecting changes in glucose control.

Serious: - Severe hypoglycemia that may lead to loss of consciousness or seizures. - Allergic reactions such as skin rash, itching, or swelling that could progress to anaphylaxis. - Liver enzyme elevations indicating possible hepatic injury. - Blood cell abnormalities such as leukopenia or thrombocytopenia.

When prescribing Glucolón, clinicians should consider several precautionary measures to minimize risks and ensure safe use.

- Assess renal and hepatic function before initiating therapy, as impairment can affect drug clearance. - Verify that the patient has sufficient endogenous insulin production; sulfonylureas are ineffective in absolute insulin deficiency. - Caution patients about the risk of hypoglycemia and advise regular meal patterns. - Adjust dose or avoid use in elderly patients who may be more susceptible to adverse effects. - Review concomitant medications that may potentiate hypoglycemia, such as other antidiabetics or beta‑blockers. - Discontinue Glucolón during pregnancy or breastfeeding unless benefits outweigh potential risks.

Glucolón may interact with other medicines, altering its glucose‑lowering effect or increasing the likelihood of adverse reactions.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which can cause additive hypoglycemia. - Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole) that may raise glibenclamide plasma levels. - Use with insulin therapy without dose adjustment, due to heightened hypoglycemia risk.

Use with caution: - Combination with beta‑blockers, which may mask hypoglycemia symptoms. - Concomitant use of thiazide diuretics, which can affect blood glucose control. - Use with oral anticoagulants, as glycemic fluctuations may influence INR stability. - Caution when combined with antidepressants such as SSRIs, which may alter glucose metabolism.